BILL & MELINDA GATES FOUNDATION

Centivax raised an oversubscribed $45 million Series A round led by Future Ventures to advance its universal flu vaccine through Phase I clinical trials beginning within eight months.

• Deerfield Management has secured more than $600 million for its third innovation fund, focusing on investments in drugs, medical devices, and healthcare services. • The new fund will operate from Deerfield's "Cure" campus in New York City and leverage partnerships with nearly 30 academic institutions to nurture healthcare startups. • With over $15 billion in assets under management, Deerfield's investment strategy comes amid a shift in biotech venture funding toward larger, more selective "megarounds" exceeding $100 million.

Dyadic International reported $3.5 million in total revenue for 2024, including approximately $1.9 million in milestone and license revenue, demonstrating significant progress in commercializing its proprietary protein production platforms.

Micron Biomedical has secured $43 million in total grant funding, including a recent $7.5 million grant from the Bill & Melinda Gates Foundation to support measles-rubella vaccine development and manufacturing scale-up.

Insud Pharma receives $2.7 million from the Bill & Melinda Gates Foundation to advance a sublingual oxytocin formulation for preventing postpartum hemorrhage (PPH).

Six tuberculosis vaccine candidates are currently undergoing Phase 3 clinical trials, marking a crucial step towards combating the disease and antimicrobial resistance.

NIAID-supported clinical trial demonstrates that an HIV vaccine candidate can elicit broadly neutralizing antibodies (bNAbs) targeting the membrane proximal external region (MPER) of HIV, a crucial step toward developing an effective preventive vaccine.

Evotec has joined the Bill & Melinda Gates Foundation's Global Health Discovery Collaboratory (GHDC) after receiving a $2.5 million grant to support its innovative iPSC-derived teratogenicity platform.